EP1087766A4 - Method of treatment - Google Patents

Method of treatment

Info

Publication number
EP1087766A4
EP1087766A4 EP99930327A EP99930327A EP1087766A4 EP 1087766 A4 EP1087766 A4 EP 1087766A4 EP 99930327 A EP99930327 A EP 99930327A EP 99930327 A EP99930327 A EP 99930327A EP 1087766 A4 EP1087766 A4 EP 1087766A4
Authority
EP
European Patent Office
Prior art keywords
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99930327A
Other languages
German (de)
French (fr)
Other versions
EP1087766A1 (en
Inventor
Martin X Steiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1087766A1 publication Critical patent/EP1087766A1/en
Publication of EP1087766A4 publication Critical patent/EP1087766A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP99930327A 1998-06-16 1999-06-16 Method of treatment Withdrawn EP1087766A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9812941.4A GB9812941D0 (en) 1998-06-16 1998-06-16 Method of treatment
GB9812941 1998-06-16
PCT/US1999/013623 WO1999065491A1 (en) 1998-06-16 1999-06-16 Method of treatment

Publications (2)

Publication Number Publication Date
EP1087766A1 EP1087766A1 (en) 2001-04-04
EP1087766A4 true EP1087766A4 (en) 2001-11-21

Family

ID=10833832

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99930327A Withdrawn EP1087766A4 (en) 1998-06-16 1999-06-16 Method of treatment

Country Status (20)

Country Link
EP (1) EP1087766A4 (en)
JP (1) JP2002518330A (en)
KR (1) KR20010052895A (en)
CN (1) CN1305379A (en)
AP (1) AP2000002002A0 (en)
AU (1) AU740749B2 (en)
BG (1) BG105127A (en)
BR (1) BR9911150A (en)
CA (1) CA2335236A1 (en)
CZ (1) CZ20004698A3 (en)
EA (1) EA003584B1 (en)
GB (1) GB9812941D0 (en)
HU (1) HUP0102507A3 (en)
IL (1) IL139943A0 (en)
NO (1) NO20006383L (en)
NZ (1) NZ508532A (en)
PL (1) PL345261A1 (en)
SK (1) SK19192000A3 (en)
WO (1) WO1999065491A1 (en)
ZA (1) ZA200007396B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154422A0 (en) * 2000-08-28 2003-09-17 Synthon Bv Paroxetine compositions and processes for making the same
WO2003057151A2 (en) 2001-12-28 2003-07-17 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
FR2926221A1 (en) * 2008-01-14 2009-07-17 Tassin Thomas COMPOSITIONS FOR THE ARTIFICIAL REPRODUCTION OF THE PHARMACOLOGICAL CONDITIONS OF ADDICTIVE DRUG DEPENDENCE SUCH AS OPIACES, PSYCHOSTIMULANTS, TOBACCO AND ALCOHOL, BY COMBINING NICOTINE AND A LIGAND.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024595A1 (en) * 1995-02-06 1996-08-15 Smithkline Beecham Plc New forms of paroxetin hydrochloride
WO1997034602A1 (en) * 1996-03-20 1997-09-25 Smithkline Beecham Plc Paroxetine in treatment of depression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
AU658155B2 (en) * 1990-11-24 1995-04-06 Beecham Group Plc Use of paroxetine for the treatment of senile dementia, or anorexia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024595A1 (en) * 1995-02-06 1996-08-15 Smithkline Beecham Plc New forms of paroxetin hydrochloride
WO1997034602A1 (en) * 1996-03-20 1997-09-25 Smithkline Beecham Plc Paroxetine in treatment of depression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; LEVIN EDWARD D_(A): "Sertraline attenuates hyperphagia in rats following nicotine withdrawal.", XP002173579, retrieved from DIALOG *
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1993, vol. 44, pages 51 - 61 *
See also references of WO9965491A1 *

Also Published As

Publication number Publication date
NO20006383D0 (en) 2000-12-14
NZ508532A (en) 2003-08-29
IL139943A0 (en) 2002-02-10
BG105127A (en) 2001-11-30
SK19192000A3 (en) 2001-05-10
JP2002518330A (en) 2002-06-25
EP1087766A1 (en) 2001-04-04
BR9911150A (en) 2001-03-06
HUP0102507A3 (en) 2003-12-29
AU4688599A (en) 2000-01-05
NO20006383L (en) 2000-12-14
CA2335236A1 (en) 1999-12-23
WO1999065491A1 (en) 1999-12-23
AU740749B2 (en) 2001-11-15
PL345261A1 (en) 2001-12-03
HUP0102507A2 (en) 2002-05-29
GB9812941D0 (en) 1998-08-12
CN1305379A (en) 2001-07-25
EA003584B1 (en) 2003-06-26
ZA200007396B (en) 2002-02-27
EA200100041A1 (en) 2001-06-25
AP2000002002A0 (en) 2000-12-31
CZ20004698A3 (en) 2002-02-13
KR20010052895A (en) 2001-06-25

Similar Documents

Publication Publication Date Title
GB9824436D0 (en) Methods of treatment
HU0001471D0 (en) New method of treatment
GB9715295D0 (en) Novel method of treatment
GB9712866D0 (en) Novel method of treatment
GB9707693D0 (en) Novel method of treatment
GB9715298D0 (en) Novel method of treatment
PL341667A1 (en) Method of treating cooped
GB9715306D0 (en) Novel method of treatment
GB9812941D0 (en) Method of treatment
HK1041202A1 (en) Novel method of treatment
GB9822681D0 (en) Method of treatment
GB9822459D0 (en) Method of treatment
GB9808479D0 (en) Method of treatment
GB9811961D0 (en) Method of treatment
GB9818776D0 (en) Method of treatment
EG24158A (en) Novel method of treatment
GB9824789D0 (en) Novel method of treatment
GB9824871D0 (en) Novel method of treatment
GB9824790D0 (en) Novel method of treatment
SI1135128T1 (en) Novel method of treatment
GB9800707D0 (en) Methods of treatment
GB9824208D0 (en) Methods of treatment
GB9822458D0 (en) Methods of treatment
ZA987316B (en) Method of treatment
GB9724289D0 (en) Method of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001128

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: RO PAYMENT 20001128;SI PAYMENT 20001128

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/445 A, 7A 61K 9/20 B

A4 Supplementary search report drawn up and despatched

Effective date: 20011008

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20040217

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040629

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1035669

Country of ref document: HK